vs

Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and SINOVAC BIOTECH LTD (SVA). Click either name above to swap in a different company.

AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Its COVID-19 vaccine was the target of a covert disinformation campaign by the US government and a ...

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AZN
AZN
SVA
SVA
Q2 25
$14.5B
Q2 24
$12.9B
Q2 23
$11.4B
Q2 22
$10.8B
Net Profit
AZN
AZN
SVA
SVA
Q2 25
$2.4B
Q2 24
$1.9B
Q2 23
$1.8B
Q2 22
$360.0M
Gross Margin
AZN
AZN
SVA
SVA
Q2 25
82.9%
Q2 24
83.1%
Q2 23
82.8%
Q2 22
72.2%
Operating Margin
AZN
AZN
SVA
SVA
Q2 25
24.3%
Q2 24
21.2%
Q2 23
21.5%
Q2 22
5.0%
Net Margin
AZN
AZN
SVA
SVA
Q2 25
16.9%
Q2 24
14.9%
Q2 23
15.9%
Q2 22
3.3%
EPS (diluted)
AZN
AZN
SVA
SVA
Q2 25
$1.57
Q2 24
$1.24
Q2 23
$1.17
Q2 22
$0.23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons